XCancer
Telix Pharmaceuticals

A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors

Description:

This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.

Sponsor:

Telix Pharmaceuticals

Phase:

Phase 1

Contacts:

Telix Medical Director

info@telixpharma.com

Government Study Link:

NCT05868174 - Click here to see study on

ClinicalTrials.gov

Inclusion
  • CAIX positivity in at least 75% of total lesion volume
  • At least 1 measurable lesion on CT/MRI according to RESIST 1.1 with corresponding TLX250-89Zr uptake
  • Histologically confirmed advanced or metastatic solid tumor that has progressed on or during/after recognized SoC
Exclusion
  • Prior 177Lu-TLX250 or other radioligand therapy; or any prior CAIX-targeting therapy
  • >2 prior lines of cytotoxic chemotherapy or had Grade 4 neutropenia or Grade 3/4 throbocytopenia
  • Cannot discontinue concomitant H2-blockers, PPIs, or medications that are inhibitors or inducers of CYP isoenzymes
  • >=5 bone metastases or bulky (>3cm diameter) pelvic or femoral tumors or tumor in the spine involving >3 vertebrae
  • Administration of any radionuclide within 10 half-lives of the radionuclide

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...